low-dose inhaled mannitol

Low-dose inhaled mannitol (50 mg) refers to the control arm intervention used in the Phase 3 B305 clinical trial (NCT00669331) for the treatment of non-cystic fibrosis bronchiectasis. Developed by Syntara (formerly Pharmaxis), this formulation was designed to serve as a matched comparator for the active treatment arm, which received 400 mg of inhaled dry powder mannitol (Bronchitol). Mannitol functions as an osmotic mucoactive agent; it increases the osmolarity of the airway surface liquid, drawing water into the airway to hydrate mucus and facilitate its clearance via ciliary action and cough. The 50 mg dose was intended to be sub-therapeutic while maintaining the blinding of the study by providing a similar taste and sensation to the active dose.

Other names

matched control-Syntara-bronchiectasis50mg inhaled mannitolmatched control (B305)